PXS.L Stock Analysis
PX
Uncovered
Provexis PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Provexis Plc engages in the development and commercialization of Fruitflow, an anti-thrombotic technology. The company is headquartered in Reading, Berkshire and currently employs 2 full-time employees. The company went IPO on 2005-06-24. Fruitflow is a patented natural ingredient, which helps with platelet aggregation. Fruitflow has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a range of food, beverage and dietary supplement formats. Fruitflow is a concentrated form of bioactive, which is lycopene-free and contains approximately 30 anti-platelet compounds. The firm also offers Fruitflow+ Omega-3 dietary supplement products, which are available to purchase from the Company’s Website, e-commerce Website www.fruitflowplus.com. The Company’s subsidiaries include Provexis Nutrition Limited (PNL) and Provexis Natural Products Limited (PNP).